Organization | University of the Witwatersrand

University of the Witwatersrand Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Johannesburg South Africa (1896)

Organization Overview

First Clinical Trial

2004

NCT00080119

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Chris Hani Baragwanath Hospital | Clinical HIV Research Unit, University of the Witwatersrand | Ezintsha, a subdivision of Wits Reproductive Health and HIV Institute (Wits RHI) | Ezintsha, Faculty of Health Sciences University of the Witwatersrand | Harriet Shezi Children's Clinic, Chris Hani Baragwanth Hospital, WHI, University of the Witwatersrand | Jeffrey Kotzen | Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital | Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand | Perinatal HIV Research Unit of the University of the Witswatersrand | Perinatal HIV Research Unit of the University of the Witwatersrand | Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Hospital | Perinatal HIV Research Unit, University of Witwatersrand | RHRU National Office, University of Witwatersand, Johannesburg | Senior Radiation Oncologist | Shabir Madhi | Student - PhD Candidate | Univeristy of the Witwatersrand | University of the Witwatersrand. Themba Lethu Clinic. | University of the Witwatersrand, Thembaletu Clinic, Helen Joseph Hospital | University of Witwatersrand | University of Witwatersrand, South Africa | University of Witwatetersrand & Charlotte Maxek Johannestburg Academic Hospital | University or Witswatersrand | VPD- RMPRU | Willem Daniel Francois Venter | Wits Reproductive Health & HIV Institute, University of the Witswatersrand

Active Ingredients

Drugs in Phase 4 Trials (22)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia) (1 trial)

attenuated measles vaccine - Edmonston strain (rubeovax) (1 trial)

chadox1 (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

fentanyl (Innovar) (1 trial)

hepatitis a vaccine, inactivated (vaqta) (1 trial)

inactivated influenza vaccine (7 trials)

inactivated varicella vaccine (1 trial)

indomethacin (indocin) (1 trial)

lamivudine (epivir) (10 trials)

levobupivacaine (chirocaine) (1 trial)

lopinavir (Kaletra) (8 trials)

morphine (1 trial)

nevirapine (viramune) (5 trials)

nicotine (nicorette) (2 trials)

norgestrel (Ovral) (1 trial)

ritonavir (Norvir) (7 trials)

split virion influenza vaccine (1 trial)

stavudine (zerit) (5 trials)

tenofovir (viread) (9 trials)

varenicline (chantix) (1 trial)

zidovudine (retrovir) (3 trials)

Drugs in Phase 3 Trials (35)

abacavir (ziagen) (2 trials)

alvac-hiv vaccine (1 trial)

bedaquiline (sirturo) (1 trial)

bivalent subtype c gp120 (1 trial)

cabotegravir (Vocabria) (1 trial)

chlorhexidine (hibitane) (1 trial)

cisplatin (platinol) (1 trial)

clofazimine (lamprene) (1 trial)

darunavir (prezista) (1 trial)

delamanid (1 trial)

desflurane (suprane) (2 trials)

didanosine (videx) (1 trial)

dolutegravir (tivicay) (1 trial)

doravirine (pifeltro) (3 trials)

efavirenz (sustiva) (4 trials)

emtricitabine (emtriva) (2 trials)

ethambutol (myambutol) (2 trials)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (2 trials)

hydroxychloroquine (plaquenil) (1 trial)

inclisiran (Leqvio) (1 trial)

isoniazid (nydrazid) (4 trials)

levofloxacin (levaquin) (1 trial)

linezolid (zyvox) (1 trial)

Molnupiravir (1 trial)

multi-valent pneumococcal conjugate vaccine (1 trial)

nitazoxanide (Alinia) (2 trials)

platelet-rich plasma (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

povidone-iodine (betadine) (1 trial)

pyrazinamide (Aldinamide) (2 trials)

sodium chloride (1 trial)

tenofovir alafenamide (genvoya) (3 trials)

thrombin (bovine) (Thrombostat) (1 trial)

triazavirin (1 trial)

trimethoprim (1 trial)

Drugs in Phase 2 Trials (15)

acetylsalicylic acid (aspirin) (1 trial)

acrivastine (Semprex-D) (1 trial)

aip-303 (1 trial)

chadox1 n-cov vaccine (1 trial)

daclatasvir (daklinza) (1 trial)

ibuprofen (motrin) (1 trial)

matrix m1 (1 trial)

mrkad5 hiv-1 gag/pol/nef (1 trial)

pravastatin (pravachol) (1 trial)

pseudoephedrine (Benylin) (1 trial)

pyridoxine (1 trial)

rifampin (2 trials)

sars-cov-2 rs (1 trial)

sofosbuvir (sovaldi) (1 trial)

trivalent p2vp8 subunit rotavirus vaccine (1 trial)

Drugs in Phase 1 Trials (6)

ch505tf gp120 (1 trial)

gla-se (1 trial)

rifabutin (mycobutin) (1 trial)

saavi dna-c2 vaccine (1 trial)

saavi mva-c vaccine (1 trial)

Drugs in Other Trials (6)

bifidobacterium animalis (1 trial)

bifidobacterium longum (1 trial)

maraviroc (selzentry) (1 trial)

misoprostol (cytotec) (1 trial)

pneumococcal protein vaccine (1 trial)

rabies vaccine (purified chick embryo cell vaccine) (RabAvert) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 4)

Breast Neoplasms (Phase 2)

Chickenpox (Phase 4)

Communicable Diseases (Phase 3)

Coronavirus Infections (Phase 3)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Fever (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Herpes Simplex (Phase 3)

Herpes Zoster (Phase 4)

HIV Infections (Phase 4)

Hypercholesterolemia (Phase 3)

Hyperlipoproteinemia Type II (Phase 3)

Immunologic Deficiency Syndromes (Phase 4)

Infections (Phase 3)

Influenza, Human (Phase 4)

Latent Tuberculosis (Phase 2)

Measles (Phase 4)

Meningitis (Phase 3)

Pain, Postoperative (Phase 4)

Papillomavirus Infections (Phase 3)

Pneumonia (Phase 4)

Pneumonia, Pneumocystis (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Squamous Intraepithelial Lesions of the Cervix (Phase 3)

Surgical Wound Infection (Phase 3)

Tuberculosis (Phase 4)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 2)

Uterine Cervical Dysplasia (Phase 2)

Uterine Cervical Neoplasms (Phase 3)

Varicose Ulcer (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 63
# of Trial APIs: 84